Consistent with these reports, we found that ADT and treatment with the AMPK activators metformin and AICAR, which cause a reduction of FASN gene and protein expression and lipogenesis, sensitized LNCaP cells to FASN inhibition by TCS (Figs. 2G-2I), suggesting that combination therapy of FASN inhibitors with ADT and/or AMPK activators (metformin, AICAR, MT 63-78) might improve the clinical outcome of PCa patients. This evidence concerns the gene FASN and posterior cortical atrophy.